Ixekizumab research highlights psoriasis news from the AAD annual meeting

Research presented on the continued efficacy of Taltz through week 60 in patients with psoriasis was among the highlights of the American Academy of Dermatology Annual Meeting in Washington, D.C.

Taltz (ixekizumab, Eli Lilly and Company) was approved this week by the FDA as treatment for adults with plaque psoriasis.

Cyndi Lauper

Other highlights from the AAD annual meeting included Cyndi Lauper discussing her psoriasis diagnosis and treatment in a video perspective:

Ixekizumab, Consentyx show efficacy in year-long treatment of psoriasis

WASHINGTON — Research from two separate studies showing year-long efficacy results of for ixekizumab and Cosentyx treatments for psoriasis were presented at a late-breaking research forum at the American Academy of Dermatology Annual Meeting.

“Intermediate long-term [studies] show good, continuous efficacy,” Joel M. Gelfand, MD, MSCE, who served as moderator for the session, told Healio.com/Dermatology. “But we still need longer studies to reflect a real-world setting that will be 2, 3, 4 years of these therapies.” Read more

VIDEO: Ixekizumab shows continued efficacy for 60-week treatment of psoriasis

WASHINGTON — In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his research showing that ixekizumab (Eli Lilly and Company) had continued efficacy in treating patients with psoriasis through week 60.

Andrew Blauvelt

Blauvelt, president and investigator of Oregon Medical Research Center, Portland, presented results from the UNCOVER-3 study at a late-breaking research forum. Watch video

VIDEO: Researcher provides update on biosimilars and psoriasis

WASHINGTON — In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his presentation about updates on biosimilars.

Blauvelt, the head of the Biosimilars Working Group for the International Psoriasis Council, focused on how biosimilars would specifically work for patients with psoriasis. Watch video

VIDEO: Cyndi Lauper discusses psoriasis at AAD

WASHINGTON – In a video perspective from the American Academy of Dermatology Annual Meeting, Cyndi Lauper discusses psoriasis diagnosis and treatment.

Lauper, who was diagnosed with psoriasis in 2010, has partnered with the National Psoriasis Foundation and Novartis Pharmaceuticals on the “I’m PsO Ready” campaign. She participated in a Novartis-sponsored question-and-answer session at the AAD meeting before conducting the video perspective with Healio.com/Dermatology. Watch video